Recommended Citation
Younossi Z, Yılmaz Y, Yu ML, Wong VWS, Castellanos-Fernandez M, Isakov V, Duseja AK, Méndez-Sánchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis G, Chan WK, Alswat K, Hamid SS, Singal A, Gomez MR, Gordon SC, Roberts S, El Kassas M, Kugelmas M, Ong J, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, and Stepanova M. Lean non-alcoholic fatty liver disease patients from the global NASH registry. J Hepatol 2022; 77:S154-S155.
Document Type
Conference Proceeding
Publication Date
7-2022
Publication Title
J Hepatol
Abstract
Background and aims: Although vast majority of patients with NAFLD are overweight and obese, NAFLD can be seen among lean individuals. The aim was to assess prevalence of lean NAFLD in different regions of the world.
Method: The Global NASH Registry enrolled patients with an established diagnosis of NAFLD from real-world practices in 18 countries (Australia, China, Cuba, Egypt, Greece, Hong Kong, India, Italy, Japan, Saudi Arabia, Malaysia, Mexico, Pakistan, Russia, Spain, Taiwan, Turkey, USA) in 6 out of 7 Global Burden of Disease (GBD) super-regions. Clinical and patient-reported outcomes (PRO) data (CLDQ-NASH, FACIT-F,WPAI) were collected. Lean NAFLD was defined as NAFLD in patients with BMI/m2, or 23 kg/m2 for patients of East Asian origin.
Results: There were 6096 NAFLD patients included (as of November 10, 2021): 48% from High-Income super-region, 24% Middle East and North Africa (MENA), 12% Southeast Asia, 7% Latin America, 6% from Eastern Europe and Central Asia, and 3% South Asia super-region. Of these, 7.3% were lean. The rates of lean NAFLD were the highest in Southeast Asia (12%) and South Asia (31%), the lowest in Eastern Europe and Central Asia (
Conclusion: Lean NAFLD patients seen in real-world practices across the world have different clinical and PRO profiles in comparison to NAFLD patients who are overweight or obese.
Volume
77
First Page
S154
Last Page
S155
